Clinical trials: Alzheimer Disease 1
Alzheimer's Disease, Mild Cognitive Impairment
A Light Exposure Tracker Designed to Improve Circadian Rhythms - Aim 1
The purpose of this research study is to investigate the relationship between reminder messages sent via text and compliance with a daily morning light intervention designed to advance the circadian clock.
- Trial name
- NCT06356337
- Testing
- Light goggles, Daily reminder test message
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Alzheimer Disease, Alzheimer Disease 1
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)
This is a randomized, double-blind, sham-controlled pivotal study of sensory stimulation in subjects with mild to moderate AD. Up to approximately 670 subjects will be treated with either Active or Sham investigational device…
- Conditions
- Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- HOPE (NCT05637801)
- Testing
- Spectris™ AD - Active
- Where
- 68 sites in United States
- Volunteers
- 673 people
- Sponsor
- Cognito Therapeutics, Inc.
Alzheimer's Disease, Huntington Disease
A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)
This study will evaluate four different modified release formulation to estimate the amount of dimebon available to the body relative to the current dimebon formulation that is given three times a day.
- Trial name
- NCT00988624
- Testing
- Dimebon IR Tablet, Dimebon MR1, Dimebon MR2
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer Disease
Phase 1 Study of OLX-07010 in Healthy Adult and Elderly Participants
This First-in-human (FIH) study will evaluate the safety, tolerability, and pharmacokinetics of the tau self-association inhibitor, OLX-07010 in single ascending doses (SAD) and multiple ascending doses (MAD) in healthy adults…
- Trial name
- NCT05696483
- Testing
- OLX-07010 Active
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Oligomerix, Inc
Alzheimer Disease
A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects
The purpose of this study is to evaluate the PK, safety, and tolerability of a new liquid formulation of tricaprilin.
- Trial name
- NCT05408780
- Testing
- AC-OLE-01-VA
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Cerecin
Alzheimer Disease
Efficacy and Safety of Talsaclidine (Free Base) in Patients With Mild to Moderate Dementia of Alzheimer Type
Study to assess symptomatic efficacy, safety and tolerability of talsaclidine in patients with mild to moderate dementia of Alzheimer type
- Trial name
- NCT02249351
- Testing
- Talsaclidine
- Volunteers
- 54 people
- Sponsor
- Boehringer Ingelheim
Alzheimer's Disease
A Study to Evaluate the Effect of Heat Application on the Delivery Profile of Corplex™ Donepezil Transdermal Delivery System (TDS)
A study to assess the effect of heat application on the delivery profile of Corplex™ Donepezil Transdermal Delivery System (TDS)
- Trial name
- NCT03438604
- Testing
- Donepezil TDS
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Corium, Inc.
Neurodegenerative Diseases, Alzheimer's Disease
A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease
SNP318 is developed to treat neurodegenerative diseases including Alzheimer's disease. In the current phase 1 study, the IP is tested in healthy volunteers, and the purpose is to investigate the safety, tolerability, and PK of…
- Trial name
- NCT05792163
- Testing
- SNP318 (A)
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- SciNeuro
Alzheimer Disease
Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers
This an open label study to assess the pharmacokinetics of CT1812 in normal healthy volunteers.
- Trial name
- COG0107 (NCT05248672)
- Testing
- CT1812
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Cognition Therapeutics
Anthrax Infection
A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines
The purpose of this study is to evaluate 2 vaccine candidates against anthrax compared to the positive (vaccine) control as studied in normal healthy volunteers.
- Trial name
- NCT01979406
- Testing
- AVA, Ad4-PA-1, Ad4-PA-GPI-1
- Where
- 4 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Alzheimer Disease
A Study of Possibility of Using Regulatory T Cells(VT301) for Treatment of Alzheimer's Disease
The overall study methods are as follows. [Clinical Trials Schedules] The study consists of a screening period(Visit 1) of up to 30 to 50 days, blood collection visits(Visit 2) for IP generation and administration visits for IP…
- Trial name
- NCT05016427
- Testing
- VT301
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- VTBIO Co. LTD
Alzheimer's Disease
A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease
The purpose of this study is to examine the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single dose of PF-04360365 in Japanese subjects with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00607308
- Testing
- PF-04360365
- Where
- 9 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Pfizer
Alzheimer's Disease
A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease
This is a Phase I, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7105705 in two participant populations: healthy participants and…
- Trial name
- NCT02820896
- Testing
- RO7105705
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Alzheimer's Disease
Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease
The purpose of the study is to examine the safety and tolerability of a multiple dose of PF-04360365 administered over approximately 10 minutes in Japanese patients with mild-to-moderate Alzheimer's disease and to characterize…
- Trial name
- NCT01125631
- Testing
- PF-04360365 8.5 mg/kg
- Where
- 4 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Pfizer
Mild Cognitive Impairment
Rhythmic Light Therapy for Alzheimer's Disease Patients
The investigator will investigate how light delivering 40 hertz (Hz) affects subjective sleep and cognition in a controlled laboratory study.
- Trial name
- NCT05015478
- Testing
- Tailored Rhythmic Lighting Intervention
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Alzheimer's Disease
Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease
This study is being done to evaluate the safety, tolerability and potential effectiveness of a new investigational drug, bryostatin 1, in patients with Alzheimer's disease (AD).
- Trial name
- NCT02221947
- Testing
- Bryostatin 1
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Neurotrope Bioscience, Inc.